Clinical trials: Disruptive Behavior
Attention Deficit Hyperactivity Disorder
Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
The objective is to assess overall safety and tolerability of atomoxetine in doses up to 120 mg/day in Japanese adult patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for…
- Trial name
- NCT00530335
- Testing
- Atomoxetine
- Where
- 12 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
- Trial name
- NCT03420222
- Testing
- AVP-786
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.
- Trial name
- NCT00254462
- Testing
- Atomoxetine, Parent Training
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- University of Nebraska
Attention Deficit/Hyperactivity Disorder(ADHD)
Effect of Vyvanse on Driving in Young Adults With ADHD
The primary objective of the study is to assess the benefice of Vyvanse on the factors that cause impairments in driving behavior in individuals with ADHD using a driving simulation aimed at examining the factors that cause…
- Trial name
- NCT00801229
- Testing
- Vyvanse
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse
This is an open label pilot study to obtain information on the best way to study young adolescents with Attention Deficit Hyperactivity Disorder (ADHD)who may also be at risk of developing substance abuse, in part because of…
- Trial name
- NCT00573534
- Testing
- Vyvanse
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Hyperactivity Disorder
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)
With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal…
- Trial name
- NCT04081363
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Trigeminal Nerve Stimulation for ADHD
The purpose of this study is to develop external Trigeminal Nerve Stimulation (eTNS) as a potential nonmedication treatment for attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- TNS for ADHD (NCT02155608)
- Testing
- Active eTNS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, Los Angeles
ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03460652
- Testing
- KP415 oral capsule
- Where
- 19 sites in United States
- Volunteers
- 282 people
- Sponsor
- Zevra Therapeutics
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child
Triple P forADHD Children's Mothers, Education of Behavioral Problems, and Change in Mothers' Attitude
The goal of this clinical trial is to investigate whether the Triple P program will reduce behavioral problems for ADHD children, improve mothers' sense of competency, and improve their attitudes The main questions it aims to…
- Conditions
- ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child, ADHD - Attention Deficit Disorder With Hyperactivity, Healthy Adult Females
- Trial name
- (ADHD) (NCT07069621)
- Testing
- Triple p level parenting program
- Where
- Palestinian Territories
- Volunteers
- 67 people
- Sponsor
- Palestine Polytechnic University
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
This study investigates whether OROS-methylphenidate improves performance on different aspects of attention and memory in children with Attention-Deficit Hyperactivity Disorder (ADHD).
- Trial name
- CHOP (NCT00530257)
- Testing
- OROS-methylphenidate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Attention Deficit Disorder With Hyperactivity
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
This study will determine the effectiveness of group cognitive-behavioral therapy as compared to a problem-solving social support group in treating problems of time management, organization, and planning in adults with attention…
- Trial name
- NCT00278473
- Testing
- Meta-Cognitive Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Trichotillomania
Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
The goals of the study are to further design, develop, and test an awareness enhancement and monitoring device, which will be used in the self-awareness training and general treatment of patients with compulsive hair-pulling…
- Trial name
- NCT01654523
- Testing
- Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan
Attention Deficit Hyperactivity Disorder
Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)
Neurofeedback is increasingly advocated for treatment of ADHD despite a thin evidence base. The numerous open and partially controlled studies suffer serious design flaws.
- Trial name
- NCT00886483
- Testing
- Active Neurofeedback
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- L. Eugene Arnold
Attention Deficit Disorder With Hyperactivity
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
- Trial name
- Project1 (NCT00429273)
- Testing
- Guanfacine, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- University of California, Los Angeles
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD
- Trial name
- NCT03247543
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 10 sites in United States
- Volunteers
- 313 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity, Cocaine-Related Disorders
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD.
- Trial name
- Atom (NCT00218543)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute